KP
Krishnendu Pal
Mayo Clinic in Florida, Mayo Clinic Rochester, Osmania University, University Of Calcutta Department Of Chemistry, Mayo Clinic in Rochester
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · Nanoparticle-Based Drug Delivery · Angiogenesis and VEGF in Cancer · Pancreatic and Hepatic Oncology Research
0000-0002-4006-213X
Employment
-
Mayo Clinic Associate Consultant-I (AC-I)2021 - Present
-
Mayo Clinic Florida Assistant Professor2018 - Present
-
Mayo Clinic in Florida Research Associate2016 - 2021
-
Mayo Clinic Florida Senior Research Fellow2015 - 2016
-
Mayo Clinic Rochester Senior Research Fellow2015 - 2015
-
Mayo Clinic Rochester Research Fellow2012 - 2015
-
Mayo Clinic in Rochester Special Project Associate2010 - 2012
-
Indian Institute of Chemical Technology Senior Research Fellow2006 - 2010
-
Indian Institute of Chemical Technology Junior Research Fellow2004 - 2006
Education
- 2004 - 2010
-
University Of Calcutta Department Of Chemistry M Sc2002 - 2004
-
University Of Calcutta Department Of Chemistry B Sc1998 - 2002
Projects & Funding
-
Restoring immune-vascular axis integrity to alleviate acute lung injury in sepsis National Heart Lung and Blood Institute2022 - 2023
-
Overriding Radiation Therapy Resistance and Enhancing the Abscopal Effect in Renal Cancer Congressionally Directed Medical Research Programs2021 - 2025
Publications (38)
- Strategic trimodal therapy enhances radiation-induced abscopal response in renal cancer. Save
- Structural and Functional Perspectives of Optineurin in Autophagy, Immune Signaling, and Cancer Save
- Lipid Nanoparticle-Mediated RNAi Against GIPC1 Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma Save
- Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma. Save
- Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Save
- Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe. Save
- Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. Save
- Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Save
- Dissecting VEGF-induced acute versus chronic vascular hyperpermeability: Essential roles of dimethylarginine dimethylaminohydrolase-1. Save
- Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer Save
- Synchronous inhibition of mTOR and VEGF/NRP1 axis impedes tumor growth and metastasis in renal cancer Save
- Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. Save
- Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma. Save
- Molecular Inhibitor of QSOX1 Suppresses Tumor Growth in vivo. Save
- BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Save
- Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC. Save
- Abstract 705: Tumor intrinsic PD-L1 is mediated byBRAFV600Eand can regulate drug-induced apoptosis in human colon cancer Save
- Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Save
- VEGF receptor-1 modulates amyloid β 1-42 oligomer-induced senescence in brain endothelial cells. Save
- Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer. Save